Chapter 4 : Cryptococcosis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Cryptococcosis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555817879/9781555812607_Chap04-1.gif /docserver/preview/fulltext/10.1128/9781555817879/9781555812607_Chap04-2.gif


In patients with recognizable disease, the symptoms of pulmonary cryptococcosis may be mild and are typically chronic. It is likely that both reactivation of previous infection and primary progressive infection can cause CNS cryptococcosis in patients with AIDS. Given the frequent lack of inflammatory responses in patients with cryptococcosis and the possibility of enhancing the immune response by adjuvant type therapy, the factors involved in regulating the production of TH1 immunity to infection have received a great deal of study. Natural killer (NK) cells are also important in promoting the development of TH1 cells from naive TH cells during pulmonary cryptococcosis, primarily via the production of IFN- γ. Administration of IL-12 to wild-type mice enhances IFN- production, promotes clearance of , and prevents dissemination to the brain. In this study, pulmonary cryptococcosis was associated with almost no expression of TH1 mRNAs, but some TH2 mRNAs. Production of TNF-α in mice with pulmonary cryptococcosis occurs early during infection and also appears necessary for the development of protective TH1 immunity and macrophage activation. Nevertheless, neutralization of either MCP1 or MIP-1α in mice with pulmonary cryptococcosis results in reduced macrophage and leukocyte recruitment and impaired fungal clearance. Since control of cryptococcosis is associated with strong granulomatous responses, immune therapeutic approaches have focused on measures that stimulate cellular-mediated immunity.

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4

Key Concept Ranking

Tumor Necrosis Factor alpha
Central Nervous System Diseases
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 1
Figure 1

India ink stain of CSF from rat with experimental meningitis. Note large capsules of organisms.

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

(A) Granulomatous inflammation in the meninges of rat with experimental cryptococcal meningitis. Arrows point to iNOS-expressing cells. (B) Rat lung, 1 year after pulmonary infection with (mucin stain). Lung contains small granulomatous foci with organisms. (C) Lung from NOS2 mouse infected with Intense granulomatous inflammation is present. Arrow points to (Photo courtesy of J. Rivera.) (D) Lung from wild-type (parental) mouse infected with A large number of organisms are present and form collections that distend alveoli. Minimal organized inflammation is present. (Photo courtesy of J. Rivera.)

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Abe, K.,, J. Kadota,, Y. Ishimatsu,, T. Iwashita,, K. Tomono,, K. Kawakami,, and S. Kohno. 2000. Th1-Th2 cytokine kinetics in the bronchoalveolar lavage fluid of mice infected with Cryptococcus neoformans of different virulences. Microbiol. Immunol. 44:849855.
2. Aguirre, K. M.,, and G. W. Gibson. 2000. Differing requirement for inducible nitric oxide synthase activity in clearance of primary and secondary Cryptococcus neoformans infection. Med. Mycol. 38:343353.
3. Allende, M.,, P. A. Pizzo,, M. Horowitz,, H. I. Pass,, and T. J. Walsh. 1993. Pulmonary cryptococcosis presenting as metastases in children with sarcomas. Pediatr. Infect. Dis. J. 12:240243.
4. Almeida, G. M.,, R. M. Andrade,, and C. A. Bento. 2001. The capsular polysaccharides of Cryptococcus neoformans activate normal CD4(+) T cells in a dominant Th2 pattern. J. Immunol. 167:58455851.
5. Banerjee, U.,, K. Datta,, T. Majumdar,, and K. Gupta. 2001. Cryptococcosis in India: the awakening of a giant? Med. Mycol. 39:5167.
6. Blackstock, R. 1996. Cryptococcal capsular polysaccharide utilizes an antigen-presenting cell to induce a T-suppressor cell to secrete TsF. J. Med. Vet. Mycol. 34:1930.
7. Blackstock, R.,, K. L. Buchanan,, A. M. Adesina,, and J. W. Murphy. 1999. Differential regulation of immune responses by highly and weakly virulent Cryptococcus neoformans isolates. Infect. Immun. 67:36013609.
8. Blackstock, R.,, N. K. Hall,, and N. C. Hernandez. 1989. Characterization of a suppressor factor that regulates phagocytosis by macrophages in murine cryptococcosis. Infect. Immun. 57:17731779.
9. Blackstock, R.,, N. McElwee,, E. Neller,, and J. Shaddix-White. 2000. Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): requirements for GXM, APC activation, and interleukin-12. Infect. Immun. 68:51465153.
10. Bunting, L. A.,, J. B. Neilson,, and G. S. Bulmer. 1979. Cryptococcus neoformans: gastronomic delight of a soil ameba. Sabouraudia 17:225232.
11. Campbell, G. D. 1966. Primary pulmonary cryptococcosis. Am. Rev. Respir. Dis. 94:236243.
12. Casadevall, A.,, W. Cleare,, M. Feldmesser,, A. Glatman-Freedman,, D. L. Goldman,, T. R. Kozel,, N. Lendevai,, J. Mukherjee,, L.-A. Pirofski,, J. Rivera,, A. L. Rosas,, M. D. Scharff,, P. Valadon,, K. Westin,, and Z. Zhong. 1998. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is candidate for human therapeutic studies. Infect. Immun. 42:14371446.
13. Casadevall, A.,, A. L. Rosas,, and J. D. Nosanchuk. 2000. Melanin and virulence in Cryptococcus neoformans. Curr. Opin Microbiol. 3:354358.
14. Cauley, L. K.,, and J. W. Murphy. 1979. Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect. Immun. 23: 644651.
15. Chaka, W.,, R. Heyderman,, I. Gangaidzo,, V. Robertson,, P. Mason,, J. Verhoef,, A. Verheul,, and A. I. Hoepelman, and the University of Zimbabwe Meningitis Group. 1997. Cytokine profiles in cerebrospinal fluid of human immunodeficiency virus-infected patients with cryptococcal meningitis: no leukocytosis despite high interleukin- 8 levels. J. Infect. Dis. 176:16331636.
16. Chaka, W.,, A. F. Verheul,, and A. I. Hoepelman. 1997. Influence of different condition on kinetics of tumor necrosis factor alpha release by peripheral blood mononuclear cells after stimulation with Cryptococcus neoformans: a possible explanation for different results. Clin. Diagn. Lab. Immunol. 4:792794.
17. Chaka, W.,, A. F. Verheul,, V. V. Vaishnav,, R. Cherniak,, J. Scharringa,, J. Verhoef,, H. Snippe,, and I. M. Hoepelman. 1997. Cryptococcus neoformans and cryptococcal glucuronoxylomannan, galactoxylomannan, and mannoprotein induce different levels of tumor necrosis factor alpha in human peripheral blood mononuclear cells. Infect. Immun. 65:272278.
18. Chiapello, L.,, P. Iribarren,, L. Cervi,, H. Rubinstein,, and D. T. Masih. 2001. Mechanisms for induction of immunosuppression during experimental cryptococcosis: role of glucuronoxylomannan. Clin. Immunol. 100:96106.
19. Cinti, S. K.,, W. S. Armstrong,, and C. A. Kauffman. 2001. Case report. Recurrence of increased intracranial pressure with antiretroviral therapy in an AIDS patient with cryptococcal meningitis. Mycoses 44:497501.
20. Clemons, K. V.,, J. E. Lutz,, and D. A. Stevens. 2001. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob. Agents Chemother. 45:686689.
21. Coenjaerts, F. E.,, A. M. Walenkamp,, P. N. Mwinzi,, J. Scharringa,, H. A. Dekker,, J. A. van Strijp,, R. Cherniak,, and A. I. Hoepelman. 2001. Potent inhibition of neutrophil migration by cryptococcal mannoprotein-4-induced desensitization. J. Immunol. 167: 39883995.
22. Collins, H. L.,, and G. J. Bancroft. 1991. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses. Infect Immun. 59:38833888.
23. Cox, G. M.,, J. Mukherjee,, G. T. Cole,, A. Casadevall,, and J. R. Perfect. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect. Immun. 68:443448.
24. Currie, B. P.,, and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19: 10291033.
25. Del Poeta, M.,, D. L. Toffaletti,, T. H. Rude,, S. D. Sparks,, J. Heitman,, and J. R. Perfect. 1999. Cryptococcus neoformans differential gene expression detected in vitro and in vivo with green fluorescent protein. Infect. Immun. 67:18121820.
26. DeShaw, M.,, and L.-A. Pirofski. 1995. Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals. Clin. Exp. Immunol. 99:425432.
27. Dong, Z. M.,, L. Jackson,, and J. W. Murphy. 1999. Mechanisms for induction of Lselectin loss from T lymphocytes by a cryptococcal polysaccharide, glucuronoxylomannan. Infect. Immun. 67:220229.
28. Dong, Z. M.,, and J. W. Murphy. 1996. Cryptococcal polysaccharide induces L-selectin shedding and tumor necrosis factor receptor loss from the surface of human neutrophils. J. Clin. Investig. 97:689698.
29. Dong, Z. M.,, and J. W. Murphy. 1997. Cryptococcal polysaccharide binds to CD18 on human neutrophils. Infect. Immun. 65:557563.
30. Dromer, F.,, and J. Charreire. 1991. Improved amphotericin B activity by a monoclonal anti-Cryptococcus neoformans antibody: study during murine cryptococcosis and mechanisms of action. J. Infect. Dis. 163:11141120.
31. Facchetti, F.,, W. Vermi,, S. Fiorentini,, M. Chilosi,, A. Caruso,, M. Duse,, L. D. Notarangelo,, and R. Badolato. 1999. Expression of inducible nitric oxide synthase in human granulomas and histiocytic reactions. Am. J. Pathol. 154:145152.
32. Feldmesser, M.,, and A. Casadevall. 1997. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection. J. Immunol. 158:790799.
33. Feldmesser, M.,, Y. Kress,, and A. Casadevall. 1998. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans. J. Infect. Dis. 177:16391646.
34. Feldmesser, M.,, Y. Kress,, P. Novikoff,, and A. Casadevall. 2000. Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect. Immun. 68:42254237.
35. Feldmesser, M.,, J. Mukherjee,, and A. Casadevall. 1996. Combination of 5-flucytosine and capsule binding monoclonal antibody in therapy of murine Cryptococcus neoformans infections and in vitro. J. Antimicrob Chemother. 37:617622.
36. Flesch, I. E.,, G. Schwamberger,, and S. H. Kaufmann. 1989. Fungicidal activity of IFNgamma- activated macrophages. Extracellular killing of Cryptococcus neoformans. J. Immunol. 142:32193224.
37. Fleuridor, R.,, R. H. Lyles,, and L. Pirofski. 1999. Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. J. Infect. Dis. 180:15261535.
38. Garcia-Hermoso, D.,, G. Janbon,, and F. Dromer. 1999. Epidemiological evidence for dormant Cryptococcus neoformans infection. J. Clin. Microbiol. 37:32043209.
39. Goldman, D.,, Y. Cho,, M.-L. Zhao,, A. Casadevall,, and S. C. Lee. 1996. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am. J. Pathol. 148:12751282.
40. Goldman, D.,, X. Song,, R. Kitai,, A. Casadevall,, M.-L. Zhao,, and S. C. Lee. 2001. Cryptococcus neoformans induces macrophage inflammatory protein 1α (MIP-1α) and MIP- 1β in human microglia: role of specific antibody and soluble capsular polysaccharide. Infect. Immun. 69:18081815.
41. Goldman, D. L.,, A. Casadevall,, Y. Cho,, and S. C. Lee. 1996. Cryptococcus neoformans meningitis in the rat. Lab. Invest. 75:759770.
42. Goldman, D. L.,, B. C. Fries,, S. P. Franzot,, L. Montella,, and A. Casadevall. 1998. Phenotypic switching in the human pathogenic fungus Cryptococcus neoformans is associated with changes in virulence and pulmonary inflammatory response in rodents. Proc. Nat. Acad. Sci. USA 95:1496714972.
43. Goldman, D. L.,, H. Khine,, J. Abadi,, D. J. Lindenberg,, L.-A. Pirofski,, R. Niang,, and A. Casadevall. 2001. Serologic evidence for cryptococcus neoformans infection in early childhood. Pediatrics 107:e66. [Online.]
44. Goldman, D. L.,, S. C. Lee,, A. J. Mednick,, L. Montella,, and A. Casadevall. 2000. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression and al tered antibody responsiveness to cryptococcal polysaccharide. Infect. Immun. 68:832838.
45. Gordon, M. A.,, and A. Casadevall. 1995. Serum therapy of cryptococcal meningitis. Clin. Infect. Dis. 21:14771479.
46. Gordon, M. A.,, and E. Lapa. 1964. Serum protein enhancement of antibiotic therapy in cryptococcosis. J. Infect. Dis. 114:373378.
47. Graybill, J. R.,, L. Mitchell,, and D. J. Drutz. 1979. Host defense in cryptococcosis. III. Protection of nude mice by thymus transplantation. J. Infect. Dis. 140:546552.
48. Gyetko, M. R.,, G. H. Chen,, R. A. McDonald,, R. Goodman,, G. B. Huffnagle,, C. C. Wilkinson,, J. A. Fuller,, and G. B. Toews. 1996. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J. Clin. Investig. 97:18181826.
49. Gyetko, M. R.,, S. Sud,, G. H. Chen,, J. A. Fuller,, S. W. Chensue,, and G. B. Toews. 2002. Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J. Immunol. 168: 801809.
50. Hamilton, A. J.,, and M. D. Holdom. 1999. Antioxidant systems in the pathogenic fungi of man and their role in virulence. Med. Mycol. 37:375389.
51. Harrison, T. S.,, and S. M. Levitz. 1996. Role of IL-12 in peripheral blood mononuclear cell responses to fungi in persons with and without HIV infection. J. Immunol. 156: 44924497.
52. Haugen, R. K.,, and R. D. Baker. 1954. The pulmonary lesions in cryptococcosis with special reference to subpleural nodules. Am. J. Clin. Pathol. 24:13811390.
53. Herring, A. C.,, J. Lee,, R. A. McDonald,, G. B. Toews,, and G. B. Huffnagle. 2002. Induction of interleukin-12 and gamma interferon requires tumor necrosis factor alpha for protective T1-cell-mediated immunity to pulmonary Cryptococcus neoformans infection. Infect. Immun. 70:29592964.
54. Hidore, M. R.,, N. Nabavi,, F. Sonleitner,, and J. W. Murphy. 1991. Murine natural killer cells are fungicidal to Cryptococcus neoformans. Infect. Immun. 59:17471754.
55. Hoag, K. A.,, M. F. Lipscomb,, A. A. Izzo,, and N. E. Street. 1997. IL-12 and IFN-gamma are required for initiating the protective Th1 response to pulmonary cryptococcosis in resistant C.B-17 mice. Am. J. Respir. Cell Mol. Biol. 17:733739.
56. Hoag, K. A.,, N. E. Street,, G. B. Huffnagle,, and M. F. Lipscomb. 1995. Early cytokine production in pulmonary Cryptococcus neoformans infections distinguishes susceptible and resistant mice. Am. J. Respir. Cell Mol. Biol. 13:487495.
57. Huffnagle, G. B.,, G. H. Chen,, J. L. Curtis,, R. A. McDonald,, R. M. Strieter,, and G. B. Toews. 1995. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J. Immunol. 155:35073516.
58. Huffnagle, G. B.,, M. F. Lipscomb,, J. A. Lovchick,, K. A. Hoag,, and N. E. Street. 1994. The role of CD4+and CD8+T-cells in protective inflammatory response to a pulmonary cryptococcal infection. J. Leukoc. Biol. 55:3542.
59. Huffnagle, G. B.,, L. K. McNeil,, R. A. McDonald,, J. W. Murphy,, G. B. Toews,, M. Nobuyo,, and W. Kuziel. 1999. Role of C-C chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans. J. Immunol. 163:46424646.
60. Huffnagle, G. B.,, N. E. Street,, and M. Lipscomb. 1992. In contrast to Balb/c mice, a Cryptococcus neoformans infection in C57BL/6 mice generates protective T cell immunity in the periphery and non-protective T-cell mediated eosinophilia in the lungs. FASEB J. 6:A1689.
61. Huffnagle, G. B.,, R. M. Strieter,, L. K. McNeil,, R. A. McDonald,, M. D. Burdick,, S. L. Kunkel,, and G. B. Toews. 1997. Macrophage inflammatory protein-1 α (MIP-1α) is required for the efferent phase of pulmonary cell-mediated immunity to a Cryptococcus neoformans infection. J. Immunol. 159:318327.
62. Huffnagle, G. B.,, R. M. Strieter,, T. J. Standiford,, R. A. McDonald,, M. D. Burdick,, S. L. Kunkel,, and G. B. Toews. 1995. The role of monocyte chemotactic protein-1 (MCP- 1) in the recruitment of monocytes and CD4+ T cells during a pulmonary Cryptococcus neoformans infection. J. Immunol. 155:47904797.
63. Huffnagle, G. B.,, G. B. Toews,, M. D. Burdick,, M. B. Boyd,, K. S. McAllister,, R. A. McDonald,, S. L. Kunkel,, and R. M. Strieter. 1996. Afferent phase production of TNFalpha is required for the development of protective T cell immunity to Cryptococcus neoformans. J. Immunol. 157:45294536.
64. Huffnagle, G. B.,, J. L. Yates,, and M. F. Lipscomb. 1991. T cell-mediated immunity in the lung: a Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect. Immun. 59:14231433.
65. Jacobson, E. S. 2000. Pathogenic roles for fungal melanins. Clin. Microbiol. Rev. 13: 708717.
66. Joly, V.,, L. Saint-Julien,, C. Carbon,, and P. Yeni. 1994. In vivo activity of interferongamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J. Infect. Dis. 170:13311334.
67. Kanj, S. S.,, K. Welty-Woolf,, J. Madden,, V. Tapson,, M. A. Baez,, R. D. Davis,, and J. R. Perfect. 1996. Fungal infections in lung and heart-lung transplant recipients. Medicine 75:142156.
68. Kaplan, J. E.,, D. Hanson,, M. S. Dworkin,, T. Frederick,, J. Bertolli,, M. L. Lindegren,, S. Holmberg,, and J. L. Jones. 2000. Epidemiology of human immunodeficiency virusassociated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30(Suppl. 1):S5S14.
69. Kawakami, K.,, Y. Kinjo,, S. Yara,, Y. Koguchi,, K. Uezu,, T. Nakayama,, M. Taniguchi,, and A. Saito. 2001. Activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide results in development of Th1 response and local host resistance in mice infected with Cryptococcus neoformans. Infect. Immun. 69:213220.
70. Kawakami, K.,, Y. Koguchi,, M. H. Qureshi,, A. Miyazato,, S. Yara,, Y. Kinjo,, Y. Iwakura,, K. Takeda,, S. Akira,, M. Kurimoto,, and A. Saito. 2000. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. J. Immunol. 165: 941947.
71. Kawakami, K.,, Y. Koguchi,, M. H. Qureshi,, S. Yara,, Y. Kinjo,, K. Uezu,, and A. Saito. 2000. NK cells eliminate Cryptococcus neoformans by potentiating the fungicidal activity of macrophages rather than by directly killing them upon stimulation with IL-12 and IL-18. Microbiol. Immunol. 44:10431050.
72. Kawakami, K.,, X. Qifeng,, M. Tohyama,, M. H. Qureshi,, and A. Saito. 1996. Contribution of tumour necrosis factor-alpha (TNF-alpha) in host defence mechanism against Cryptococcus neoformans. Clin. Exp. Immunol. 106:468474.
73. Kawakami, K.,, M. H. Qureshi,, T. Zhang,, H. Okamura,, M. Kurimoto,, and A. Saito. 1997. IL-18 protects mice against pulmonary and disseminated infection with Cryptococcus neoformans by inducing IFN-gamma production. J. Immunol. 159:55285534.
74. Kawakami, K.,, M. Tohyama,, K. Teruya,, N. Kudeken,, Q. Xie,, and A. Saito. 1996. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol. Med. Microbiol. 13: 123130.
75. Kawakami, K.,, M. Tohyama,, Q. Xie,, and A. Saito. 1996. IL-12 protects mice against pulmonary and disseminated infection caused by Cryptococcus neoformans. Clin. Exp. Immunol. 104:208214.
76. Kawakami, K.,, T. Zhang,, M. H. Qureshi,, and A. Saito. 1997. Cryptococcus neoformans inhibits nitric oxide production by murine peritoneal macrophages stimulated with interferon-gamma and lipopolysaccharide. Cell. Immunol. 180:4754.
77. Kerkering, T. M.,, R. J. Duma,, and S. Shadomy. 1981. The evolution of pulmonary cryptococcosis. Ann. Intern. Med. 94:611616.
78. Lee, S. C.,, D. W. Dickson,, C. F. Brosnan,, and A. Casadevall. 1994. Human astrocytes inhibit Cryptococcus neoformans growth by a nitric oxide-mediated mechanism. J. Exp. Med. 180:365369.
79. Lee, S. C.,, D. W. Dickson,, and A. Casadevall. 1996. Pathology of cryptococcal meningoencephalitis: analysis of 27 patients with pathonenetic implications. Hum. Pathol. 27: 839847.
80. Legendre, U.,, M. Battegay,, I. Nuttli,, P. Dalquen,, and R. Nuesch. 2001. Simultaneous occurrence of 2 HIV-related immunereconstitution diseases after initiation of highly active antiretroviral therapy. Scand. J. Infect. Dis. 33:388389.
81. Lendvai, N.,, X. W. Qu,, W. Hsueh,, and A. Casadevall. 2000. Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice. J. Immunol. 164:43674374.
82. Levitz, S. M.,, M. P. Dupont,, and E. H. Smail. 1994. Direct activity of human T lymphocytes and natural killer cells against Cryptococcus neoformans. Infect. Immun. 62:194202.
83. Levitz, S. M.,, E. A. North,, Y. Jiang,, S. H. Nong,, and H. Kornfeld. 1997. Variables affecting production of monocyte chemotactic factor 1 from human leukocytes stimulated with Cryptococcus neoformans. Infect. Immun. 65:903908.
84. Levitz, S. M.,, A. Tabuni,, H. Kornfeld,, C. C. Reardon,, and D. T. Golenbock. 1994. Production of tumor necrosis factor alpha in human leukocytes stimulated by Cryptococcus neoformans. Infect. Immun. 62:19751981.
85. Lim, T. S.,, and J. W. Murphy. 1980. Transfer of immunity to cryptococcosis by Tenriched splenic lymphocytes from Cryptococcus neoformans-sensitized mice. Infect. Immun. 30:511.
86. Lipovsky, M. M.,, G. Gekker,, S. Hu,, L. C. Ehrlich,, A. I. Hoepelman,, and P. K. Peterson. 1998. Cryptococcal glucuronoxylomannan induces interleukin (IL)-8 production by human microglia but inhibits neutrophil migration toward IL-8. J. Infect. Dis. 177: 260263.
87. Lipovsky, M. M.,, L. Tsenova,, F. E. Coenjaerts,, G. Kaplan,, R. Cherniak,, and A. I. Hoepelman. 2000. Cryptococcal glucuronoxylomannan delays translocation of leukocytes across the blood-brain barrier in an animal model of acute bacterial meningitis. J. Neuroimmunol. 111:1014.
88. Lipscomb, M. F.,, T. Alvarellos,, G. B. Tows,, R. Tompkins,, Z. Evans,, G. Koo,, and V. Kumar. 1987. Role of natural killer cells in resistance to Cryptococcus neoformans infections in mice. Am. J. Pathol. 128:354361.
89. Littman, M. L.,, and R. Borok. 1968. Relation of the pigeon to cryptococcosis: natural carrier state, heat resistance and survival of Cryptococcus neoformans. Mycopathol. Mycol. Appl. 35:329345.
90. Lovchik, J. A.,, C. R. Lyons,, and M. F. Lipscomb. 1995. A role for gamma interferoninduced nitric oxide in pulmonary clearance of Cryptococcus neoformans. Am. J. Respir. Cell Mol. Biol. 13:116124.
91. Lovchik, J. A.,, J. A. Wilder,, G. B. Huffnagle,, R. Riblet,, C. R. Lyons,, and M. F. Lipscomb. 1999. Ig heavy chain complex-linked genes influence the immune response in a murine cryptococcal infection. J. Immunol. 163:39073913.
92. Lutz, J. E.,, K. V. Clemons,, and D. A. Stevens. 2000. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J. Antimicrob. Chemother. 46:437442.
93. Macher, A. M.,, J. E. Bennett,, J. E. Gadek,, and M. M. Frank. 1978. Complement depletion in cryptococcal sepsis. J. Immunol. 120:16861690.
94. Merkel, G. J.,, and B. A. Scofield. 2000. The effects of Cryptococcus neoformans-secreted antigens on tumor necrosis factor-alpha-induced intercellular adhesion molecule-1 expression on human lung epithelial cells. FEMS Immunol. Med. Microbiol. 29:329332.
95. Mody, C. H.,, M. F. Lipscomb,, N. E. Street,, and G. B. Tows. 1990. Depletion of CD4+ (L3T4+) lymphocytes in vivo impairs murine host defense to Cryptococcus neoformans. J.Immunol. 144:14721477.
96. Mody, C. H.,, C. L. Tyler,, R. G. Sitrin,, C. Jackson,, and G. B. Toews. 1991. Interferongamma activates rat alveolar macrophages for anticryptococcal activity. Am. J. Respir. Cell Mol. Biol. 5:1926.
97. Monari, C.,, T. R. Kozel,, A. Casadevall,, D. Pietrella,, B. Palazzetti,, and A. Vecchiarelli. 1999. B7 costimulatory ligand regulates development of the T-cell response to Cryptococcus neoformans. Immunology 98:2735.
98. Mukherjee, J.,, M. Feldmesser,, M. D. Scharff,, and A. Casadevall. 1995. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole activity. Antimicrob. Agents Chemother. 39:13981405.
99. Mukherjee, J.,, L. Zuckier,, M. D. Scharff,, and A. Casadevall. 1994. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with Amphotericin B. Antimicrob. Agents Chemother. 38:580587.
100. Murphy, J. W.,, and J. W. Moorhead. 1982. Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen. J. Immunol. 128:276283.
101. Murphy, J. W.,, R. L. Mosley,, and J. W. Moorhead. 1983. Regulation of cell-mediated immunity in cryptococcosis. II. Characterization of first-order T suppressor cells (Ts1) and induction of second-order suppressor cells. J. Immunol. 130:28762881.
102. Naslund, P. K.,, W. C. Miller,, and D. L. Granger. 1995. Cryptococcus neoformans fails to induce nitric oxide synthase in primed murine macrophage-like cells. Infect. Immun. 63:12981304.
103. Nosanchuk, J. D.,, A. L. Rosas,, and A. Casadevall. 1998. The antibody response to fungal melanin in mice. J. Immunol. 160:60266031.
104. Nosanchuk, J. D.,, S. Shoham,, B. C. Fries,, D. S. Shapiro,, S. M. Levitz,, and A. Casadevall. 2000. Evidence of zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient. Ann. Intern. Med. 132:205208.
105. Noverr, M. C.,, S. M. Phare,, G. B. Toews,, M. J. Coffey,, and G. B. Huffnagle. 2001. Pathogenic yeasts Cryptococcus neoformans and Candida albicans produce immunomodulatory prostaglandins. Infect. Immun. 69:29572963.
106. Olszewski, M. A.,, G. B. Huffnagle,, T. R. Traynor,, R. A. McDonald,, D. N. Cook,, and G. B. Toews. 2001. Regulatory effects of macrophage inflammatory protein 1α/CCL3 on the development of immunity to Cryptococcus neoformans depend on the expression of early inflammatory cytokines. Infect. Immun. 69:62566263.
107. Pancharoen, C.,, A. Chindamporn,, and U. Thisyakorn. 2001. Childhood cryptococcosis: an increasing problem in the era of AIDS. J. Med. Assoc. Thai 84 (Suppl.1):S86S90.
108. Perfect, J. R.,, S. D. R. Lang,, and D. T. Durack. 1980. Chronic cryptococcal meningitis. Am. J. Pathol. 101:177193.
109. Pietrella, D.,, C. Monari,, C. Retini,, B. Palazzetti,, T. R. Kozel,, and A. Vecchiarelli. 1998. Cryptococcus neoformans and Candida albicans regulate CD4 expression on human monocytes. J. Infect. Dis. 178:14641471.
110. Reardon, C. C.,, S. J. Kim,, R. P. Wagner,, and H. Kornfeld. 1996. Interferon-gamma reduces the capacity of human alveolar macrophages to inhibit growth of Cryptococcus neoformans in vitro. Am. J. Respir. Cell Mol. Biol. 15:711715.
111. Retini, C.,, A. Vecchiarelli,, C. Monari,, F. Bistoni,, and T. R. Kozel. 1998. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun. 66:664669.
112. Retini, C.,, A. Vecchiarelli,, C. Monari,, C. Tascini,, F. Bistoni,, and T. R. Kozel. 1996. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64:28972903.
113. Rivera, J.,, J. Mukherjee,, L. M. Weiss,, and A. Casadevall. 2002. Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: a role for nitric oxide. J. Immunol. 168:34193427.
114. Rosas, A. L.,, R. S. MacGill,, J. D. Nosanchuk,, T. R. Kozel,, and A. Casadevall. 2002. Activation of the alternative complement pathway by fungal melanins. Clin. Diagn. Lab. Immunol. 9:144148.
115. Rosas, A. L.,, J. D. Nosanchuk,, M. Feldmesser,, G. M. Cox,, H. C. McDade,, and A. Casadevall. 2000. Synthesis of polymerized melanin by Cryptococcus neoformans in infected rodents. Infect. Immun. 68:28452853.
116. Rossi, G. R.,, L. A. Cervi,, M. M. Garcia,, L. S. Chiapello,, D. A. Sastre,, and D. T. Masih. 1999. Involvement of nitric oxide in protecting mechanism during experimental cryptococcosis. Clin. Immunol. 90:256265.
117. Salkowski, C. A.,, and E. Balish. 1991. A monoclonal antibody to gamma interferon blocks augmentation of natural killer cell activity induced during systemic cryptococcosis. Infect. Immun. 59:486493.
118. Scrimgeour, E. M.,, and R. G. Purohit. 1984. Chronic pulmonary cryptococcosis in a Rattus rattus from Raboul, Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 78:827828.
119. Shahar, A.,, Y. Kletter,, and M. Aronson. 1969. Granuloma formation in cryptococcosis. Israel. J. Med. Sci. 5:11641172.
120. Shoham, S.,, C. Huang,, J. M. Chen,, D. T. Golenbock,, and S. M. Levitz. 2001. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166:46204626.
121. Steenbergen, J. N.,, H. A. Shuman,, and A. Casadevall. 2001. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc. Natl. Acad. Sci. USA 98:1524515250.
122. Syme, R. M.,, T. F. Bruno,, T. R. Kozel,, and C. H. Mody. 1999. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect. Immun. 67:46204627.
123. Traynor, T. R.,, A. C. Herring,, M. E. Dorf,, W. A. Kuziel,, G. B. Toews,, and G. B. Huffnagle. 2002. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J. Immunol. 168:46594666.
124. Tucker, S. C.,, and A. Casadevall. 2002. Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm. Proc. Natl. Acad. Sci. USA 99:31653170.
125. Vecchiarelli, A.,, and A. Casadevall. 1998. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res. Immunol. 149:321333.
126. Vecchiarelli, A.,, C. Monari,, C. Retini,, D. Pietrella,, B. Palazzetti,, L. Pitzura,, and A. Casadevall. 1998. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7- 2 (CD86) expression on human monocytes. Eur. J. Immunol. 28:114121.
127. Vecchiarelli, A.,, D. Pietrella,, M. Dottorini,, C. Monari,, C. Retini,, and T. Todisco. 1995. Encapsulation of Cryptococcus neoformans regulates fungicidal activity and the antigen presentation process in human alveolar macrophages. Clin. Exp. Immunol. 98:217223.
128. Vecchiarelli, A.,, C. Retini,, C. Monari,, F. Bistoni,, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64:28462849.
129. Vecchiarelli, A.,, C. Retini,, C. Monari,, and A. Casadevall. 1998. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes Tcell proliferation. Infect. Immun. 66:12441247.
130. Vecchiarelli, A.,, C. Retini,, D. Pietrella,, C. Monari,, C. Tascini,, T. Beccari,, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor alpha and interleukin-1beta secretion from human monocytes. Infect. Immun. 63:29192923.
131. Woods, M. L.,, R. MacGinley,, D. P. Eisen,, and A. M. Allworth. 1998. HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection. AIDS 12: 14911494.
132. Yuan, R.,, A. Casadevall,, J. Oh,, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify C. neoformans infections in mice. Proc. Natl. Acad. Sci. USA 94: 24832488.
133. Zhang, T.,, K. Kawakami,, M. H. Qureshi,, H. Okamura,, M. Kurimoto,, and A. Saito. 1997. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect. Immun. 65:35943599.


Generic image for table
Table 1

Activities of capsular polysaccharides that affect immune response

Citation: Goldman D, Casadevall A. 2003. Cryptococcosis, p 85-116. In Boros D (ed), Granulomatous Infections and Inflammations. ASM Press, Washington, DC. doi: 10.1128/9781555817879.ch4

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error